Table 2.
Treatment outcome reported in efficacy trials in Cameroon
| Study ID | PP PCR-corrected percentage cure rate (95% CI), day 28/day 42 | ITT PCR-corrected percentage cure rate (95% CI), day 28/day 42 |
|---|---|---|
| CMR001_ASSP | 85.9 (78.2–93.6) | 82.7 (74.5–90.9) |
| CMR001_ASAQ | 90.2 (83.8–96.6) | 86.0 (78.7–93.3) |
| CMR002_AL | 96.7 (91.8–99.1)/96.7 (91.3–98.9)a | 86.2 (79.3–91.5)/ 92.0 (85.9–95.7)a |
| CMR002_ASAQ | 95.3 (91.9–97.5)/98.1 (95.2–99.2) | 87.1 (82.6–90.8)/91.0 (89.3–95.7) |
| CMR002_DHPP | 96.3 (93.1–98.3)/96.3 (92.9–98.2) | 84.3 (79.4–88.3)/89.0 (85.3–92.8) |
| CMR003_ASAQ | 88.2 (78.1–94.7) | 85.7 (75.3–92.9) |
| CMR003_ASATPG | 100 (96.2–100) | 95.0 (88.7–98.3) |
| CMR004_ASAQ | 96.4 (87.7–99.6) | 74.0 (62.3–83.5) |
| CMR004_AL | 100 (94.2–100) | 80.5 (70.0–88.6) |
| CMR005a_ASAQ | 98.2 (90.1–99.9) | 88.3 (77.4–95.0) |
| CMR005a_ASSP | 94.7 (85.3–98.9) | 88.5 (77.8–95.2) |
| CMR005b_ASAQb | 100 (94.0–100) | 90.6 (80.7–96.5) |
| CMR005c_ASMQ | 100 (94.0–100) | 88.4 (78.4–94.8) |
| CMR005d_ASAQ | 96.5 (87.9–99.5) | 88.5 (78.1–95.3) |
| CMR005d_AL | 100 (94.0–100) | 96.8 (88.8–99.6) |
| CMR005e_ASCD | 85.0 (74.0–92.0) | 72.0 (61.3–81.5) |
| CMR005e_ASSP | 94.0 (85.8–97.9) | 87.0 (78.0–93.3) |
| CMR005f_ASAQ | 92.0 (84.3–96.7) | 88.0 (79.6–93.8) |
| CMR005f_DHPP | 98.0 (91.8–99.7) | 92.0 (84.8–96.8) |
| CMR006_ASMQ | 96.5 (93.0–98.6) | 91.0 (86.4–94.5) |
| 93.8 (89.2–96.9)c | 84.1 (78.9–72.8)c | |
| 96.6 (93.0–98.4)b |
PP per-protocol, PCR polymerase chain reaction, CI confidence interval, ITT intention-to-treat, ACPR adequate clinical and parasitological response
aFor this second study, the cure rates were reported on day 42
bKaplan–Meier estimate of the proportion of subjects with ACPR and 95% CI was similar for both day 28 and day 63 in the ASMQ arm; CMR002 assessed the efficacy on day 42
cPercentage of ACPR on day 63